⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5604754 | 0.91 | KMO (0.33) | — | |
| SCHEMBL8840038 | 0.91 | CHRNA7 (0.31) | — | |
| SCHEMBL3849087 | 0.86 | PIK3CD (0.35) | — | |
| SCHEMBL5148066 | 0.79 | DYRK1A (0.31) | — | |
| SCHEMBL3694013 | 0.71 | — | — | |
| SCHEMBL12499753 | 0.70 | PDE10A (0.31) | — | |
| SCHEMBL1450328 | 0.69 | KDM4E (0.36) | — | |
| SCHEMBL7414886 | 0.69 | — | — | |
| SCHEMBL6168180 | 0.64 | — | — | |
| SCHEMBL16033188 | 0.64 | LOX (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115536635-A | Therapeutically active compounds and methods of use thereof | 法国施维雅药厂 | 2022-12-30 | — | — | CN | claimed |
| CN-115521264-A | Therapeutically active compounds and methods of use thereof | 法国施维雅药厂 | 2022-12-27 | — | — | CN | claimed |
| US-20210292281-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA | REATA PHARMACEUTICALS, INC. (US) | 2021-09-23 | — | — | US | claimed |
| EP-3019484-B1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | LES LABORATOIRES SERVIER SAS (FR) | 2021-09-08 | — | — | EP | claimed |
| EP-3807265-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA | Reata Pharmaceuticals, Inc. (US) | 2021-04-21 | — | — | EP | claimed |
| CN-112654610-A | Pyrazole and imidazole compounds for inhibiting IL-17 and ROR gamma | 里亚塔医药公司 | 2021-04-13 | — | — | CN | claimed |
| EP-3019490-B1 | N,6-BIS(ARYL OR HETEROARYL)-1,3,5-TRIAZINE-2,4-DIAMINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | AGIOS PHARMACEUTICALS INC (US) | 2020-06-03 | — | — | EP | claimed |
| EP-3019480-B1 | 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | AGIOS PHARMACEUTICALS INC (US) | 2020-05-06 | — | — | EP | claimed |
| US-10376510-B2 | 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer | AGIOS PHARMACEUTICALS, INC. (US) | 2019-08-13 | — | — | US | claimed |
| US-10154995-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-12-18 | — | — | US | claimed |
| EP-2430021-A1 | 7-ARYL-1,2,4-TRIAZOLOÝ4,3-A¨PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | Janssen Pharmaceuticals Inc. (US) | 2012-03-21 | — | — | EP | claimed |
| US-20110319426-A1 | Substituted Isoindoles | ASTRAZENECA AB (SE) | 2011-12-29 | — | — | US | claimed |
| CN-102282140-A | New compounds 578 | — | 2011-12-14 | — | — | CN | claimed |
| EP-2367814-A1 | NEW COMPOUNDS 578 | AstraZeneca AB (SE) | 2011-09-28 | — | — | EP | claimed |
| US-20110166132-A1 | Gamma Secretase Modulators | AMGEN INC. (US) | 2011-07-07 | — | — | US | claimed |
| WO-2010130423-A1 | 7-ARYL-1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2010-11-18 | — | — | WO | claimed |
| EP-2231602-A1 | GAMMA SECRETASE MODULATORS | Amgen, Inc (US) | 2010-09-29 | — | — | EP | claimed |
| US-20100125082-A1 | NEW COMPOUNDS 578 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | claimed |
| WO-2010056196-A1 | NEW COMPOUNDS 578 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | claimed |
| WO-2009075874-A1 | GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-06-18 | — | — | WO | claimed |